Syrma SGS shares worth ₹2,618 crore become eligible for trading as lock-in period ends

1 min read     Updated on 25 Aug 2025, 04:11 AM
scanx
Reviewed by
Ashish ThakurBy ScanX News Team
whatsapptwittershare
Overview

Syrma SGS's shareholder lock-in period concluded on August 25, making 3.52 crore shares (20% of equity) eligible for trading. The unlocked shares are valued at ₹2,618.00 crore. The company recently raised ₹1,000.00 crore through a QIP, with investments from HDFC Life, Tata AIA Life, and Axis Mutual Fund. Promoter stake decreased to 42.97% by June-end. The stock is trading near its 52-week high, gaining 20% this year and more than tripling from its IPO price of ₹220.00 to close at ₹744.20 on Friday.

17620875

*this image is generated using AI for illustrative purposes only.

Syrma SGS , a prominent player in the technology sector, has reached a significant milestone as its shareholder lock-in period concluded on August 25. This development has made 3.52 crore shares, representing 20% of the company's outstanding equity, eligible for trading on the stock market.

Lock-in Period Expiry

The end of the lock-in period has unlocked shares valued at approximately ₹2,618.00 crore, based on the closing price of ₹744.20 on Friday. This event marks a crucial phase for the company, potentially impacting market dynamics and liquidity.

Recent Capital Raise

Syrma SGS recently bolstered its financial position by raising ₹1,000.00 crore through a Qualified Institutional Placement (QIP). The company issued shares to several prominent funds, including:

  • HDFC Life
  • Tata AIA Life
  • Axis Mutual Fund
  • Other institutional investors

This successful fundraising effort demonstrates strong investor confidence in the company's prospects and growth potential.

Ownership Structure

The ownership structure of Syrma SGS has seen some changes in recent months:

  • Promoter stake decreased from 46.52% at the end of March to 42.97% by the end of the June quarter.
  • This reduction in promoter holding could potentially increase the public float and enhance liquidity in the stock.

Stock Performance

Syrma SGS's stock has shown remarkable performance:

  • The stock is currently trading near its 52-week high.
  • It has gained 20% in the current year, showcasing strong momentum.
  • Most impressively, the stock has more than tripled from its Initial Public Offering (IPO) price of ₹220.00.
  • The stock closed at ₹744.20 on Friday, reflecting significant value appreciation for early investors.

Market Implications

The expiry of the lock-in period, coupled with the recent QIP and strong stock performance, could lead to increased trading activity in Syrma SGS shares. Investors and market participants will be closely watching how this development impacts the stock's liquidity and price movements in the coming days.

As the technology sector continues to evolve rapidly, Syrma SGS's financial maneuvers and market performance position it as a company to watch in the Indian stock market.

Historical Stock Returns for Syrma SGS

1 Day5 Days1 Month6 Months1 Year5 Years
-2.88%+0.38%-2.47%+75.42%+69.08%+134.43%
Syrma SGS
View in Depthredirect
like18
dislike

Syrma Johari Medtech Chairman Satyendra Johari Passes Away at 77

2 min read     Updated on 13 Aug 2025, 12:58 AM
scanx
Reviewed by
Shriram ShekharBy ScanX News Team
whatsapptwittershare
Overview

Satyendra Johari, Chairman and Managing Director of Syrma Johari Medtech Limited, a subsidiary of Syrma SGS Technology Limited, passed away on August 8, 2025, at the age of 77. The Board of Syrma Johari Medtech Limited will take steps to ensure operational continuity. Meanwhile, the parent company, Syrma SGS Technology Limited, recently completed a successful QIP, raising approximately ₹10,000.00 million by issuing 14,306,151 equity shares at ₹699.00 per share. The QIP saw significant participation from various institutional investors, with several entities being allotted more than 5% of the offered equity shares.

16572512

*this image is generated using AI for illustrative purposes only.

Syrma SGS Technology Limited's subsidiary, Syrma Johari Medtech Limited, announced the passing of its Chairman and Managing Director, Satyendra Johari, on August 8, 2025. Johari, aged 77 at the time of his death, was the founder of the subsidiary company, formerly known as Johari Digital Healthcare Limited.

Company Background

Syrma Johari Medtech Limited operates under the umbrella of Syrma SGS Technology Limited, which trades on the Bombay Stock Exchange (BSE) and National Stock Exchange (NSE) under the symbols 543573 and SYRMA, respectively.

Leadership Transition

Following Johari's passing, the Board of Syrma Johari Medtech Limited has stated that it will take necessary steps to ensure the continuity of operations.

Recent Financial Activities of Parent Company

While not directly related to Syrma Johari Medtech Limited, it's worth noting that Syrma SGS Technology Limited has recently completed a substantial qualified institutions placement (QIP) of equity shares. According to the latest LODR data:

  • The company issued 14,306,151 equity shares at ₹699.00 per share.
  • The total amount raised through this issue was approximately ₹10,000.00 million.
  • The issue price represented a discount of 4.98% to the floor price of ₹735.61 per share.
  • Following this allotment, the paid-up equity share capital of Syrma SGS Technology Limited increased from ₹17,815.80 million to ₹19,246.41 million.

Investor Interest

The QIP saw participation from various institutional investors, with several entities being allotted more than 5% of the offered equity shares:

Investor Allocation
HDFC Life Insurance Company Limited 20.00%
Tata AIA Life Insurance Company Limited (across multiple funds) 17.50%
Axis Mutual Fund Trustee Limited A/C Axis Mutual Fund A/C Axis Small Cap Fund 15.00%
HDFC Mutual Fund - HDFC Manufacturing Fund 7.50%
Bandhan Mutual Fund (across multiple funds) 7.50%
Prudential Hong Kong Limited 5.08%
ICICI Prudential Life Insurance Company Limited 5.00%
Aditya Birla Sun Life Insurance Company Limited 5.00%
Motilal Oswal Small Cap Fund 5.00%

This successful capital raise by the parent company demonstrates strong investor confidence in the Syrma group of companies, which may provide a stable foundation for Syrma Johari Medtech Limited as it navigates this period of leadership transition.

As the medtech subsidiary moves forward without its founder at the helm, the industry will be watching closely to see how the company maintains its operations and strategic direction in the coming months.

Historical Stock Returns for Syrma SGS

1 Day5 Days1 Month6 Months1 Year5 Years
-2.88%+0.38%-2.47%+75.42%+69.08%+134.43%
Syrma SGS
View in Depthredirect
like15
dislike
More News on Syrma SGS
Explore Other Articles
727.90
-21.55
(-2.88%)